GlaxoSmithKline, U.S. Department of Health and Human Services infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded GlaxoSmithKline $40 million for an initial 18-month period to develop GSK's portfolio of antibacterial candidates to treat illnesses caused by bioterrorism agents and antibiotic-resistant bacteria. If GSK and BARDA renew the partnership, the pharma is eligible for up to $200 million for a five-year period. HHS said the award is the first in which BARDA is working with a company as "strategic partners with a portfolio approach," instead of providing funding for a contract for a single medical countermeasure. ...